Navigation Links
Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
Date:5/28/2009

ORLANDO (June 1, 2009)Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies. More than one-quarter of the women in a phase I/II trial had their tumors shrink on the combination therapy.

"I think this is very promising. Neratinib induces clinically meaningful responses," says Ramona Swaby, M.D., a medical oncologist and attending physician at Fox Chase. Swaby will present the study results on Monday, June 1, at the annual meeting of the American Society of Clinical Oncology.

Trastuzumab is standard therapy for women with HER2-positive metastatic breast cancer and the majority of women respond to the treatment. However, over time some women will develop resistance to the drug and their tumors will start to grow again. For these women, alternative therapies are needed.

Both trastuzumab and neratinib inhibit the HER2 receptor expressed on the surface of HER2-positive breast cancer cells. Trastuzumab blocks the extracellular portion of the receptor, while neratinib blocks the intracellular portion. Researchers think that the combination may provide the one-two punch necessary to knock out the tumor cells.

Forty-five women with trastuzumab-resistant breast cancer enrolled in the trial. In the phase I portion of the trial, women received either 160 mg or 240 mg neratinib daily plus trastuzumab 4 mg/kg IV loading dose followed by 2 mg/kg weekly. None of the patients experienced dose limiting toxicities. The most common grade 3/4 adverse events included diarrhea (13%), nausea (4%) and vomiting (4%). The researchers saw no evidence of cardiac toxicity with the combination.

Of the 33 patients in the phase II portion of the trial who are evaluable for response, nine (27%) had an objective response to the combination therapy. Additionally, 47% were progression-free at 16 weeks, which was the primary endpoint of the trail, and the median progression-free survival was 19 weeks. Seven women continue on therapy at this time. (Updated results will be presented at the meeting.)

"Trastuzumab has certainly made a difference in patient care, but there is still room for improvement," Swaby says. "For example because trastuzumab is an antibody it does not cross the blood-brain barrier so is not effective at treating or preventing brain metastases. It is incredibly heartbreaking to think you are out of the woods and then to have brain metastases occur. Neratinib, a small molecule drug that can cross the blood-brain barrier, potentially may treat brain metastases. More studies are needed"

"The phase II data are snapshots of what this drug is capable of," Swaby says. "Phase III trials are underway, which I think is the right next step for this medicine. My patients in the study did well."


'/>"/>

Contact: Frank Hoke
Franklin.Hoke@fccc.edu
215-475-2888
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Lingraphica introduces the SmallTalk mobile accessory for aphasia
2. National Small Business Week Update: Sam's Club Announces Simplified Small Business Membership; Partnership With U.S. Chamber of Commerce, Plus Free One-Day Pass
3. Indias Non-Small-Cell Lung Cancer Drug Market Will Almost Double by 2013
4. Scientists discover how smallpox may derail human immune system
5. Make No Small Plans: M. D. Anderson Cancer Center Endeavors to Make Cancer History
6. Veterans Administration Awards Small Business' $13 Million Contract to Digitize Veterans Health Records
7. Cardinal Health to Offer Allscripts Electronic Health Record to Solo and Small Physician Groups
8. Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013
9. BlueChoice HealthPlan Adds Coverage for Young Adults and New Plans for Small Businesses
10. Exercise programs may improve symptoms in non-small cell lung cancer patients
11. Scope of Swine Flu Outbreak in Mexico Might Be Smaller Than Thought
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... A new ... schedule rates and Medicare rates for a variety of medical services in Illinois ... Evaluation of the 2015 Fee Schedule Rates in Illinois, are professional medical ...
(Date:2/9/2016)... ... February 09, 2016 , ... Establishment Labs, a global ... David Hung to the company´s Board of Directors. , “We are honored ... and an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment Labs. "David’s ...
(Date:2/9/2016)... County, CA (PRWEB) , ... February 09, 2016 , ... ... on home whitening packages. Teeth whitening is among the most popular cosmetic procedures in ... for their whitening needs. This can put them at risk of teeth whitening-related damage. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Two renowned photographers, Robert ... a photographic adventure on the island, June 14-19, 2016, hosted by Four Seasons Resort ... , After a successful debut in 2015, the Maui Photo Expedition workshop ...
(Date:2/9/2016)... ... February 09, 2016 , ... Shark Finds and Kevin Harrington, and the ... with GRIP-DRY. , GRIP-DRY is a newly patented product that has solved some of the ... the wet and early morning dew or right after a rain shower, might understand the ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the ... fourth quarter and full year 2015 financial results ... genome editing," said Edward Lanphier, Sangamo,s president and ... technology leads the therapeutic genome editing field and ... move our ground-breaking genome editing programs through IND ...
(Date:2/9/2016)... 2016 Mast Therapeutics, Inc. (NYSE MKT: ... cell disease and heart failure, today announced that it intends ... common stock in an underwritten public offering.  The offering is ... no assurance as to whether or when the offering may ... of the offering.   --> ...
(Date:2/9/2016)... , Feb. 9, 2016 The global ... 2014, and it is expected to grow with a ... the glass prefilled syringes segment dominated the global prefilled ... --> --> The global market ... rate, due to increasing geriatric population, increasing demand for ...
Breaking Medicine Technology: